80.2. Pediatric Hodgkin and Non-Hodgkin Lymphomas: Pediatric Non-Hodgkin Lymphomas

Authors
Michael P. Link, Elaine S. Jaffe, John P. Leonard

Emerging Prognostic Factors for Clinical Care

<table>
<thead>
<tr>
<th>Factor</th>
<th>Definition</th>
<th>Clinical significance</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytogenetics</td>
<td>Identification of specific cytogenetic abnormalities in malignant cells</td>
<td>Specific rearrangements have prognostic significance, e.g., 13q deletion.</td>
<td>I</td>
</tr>
<tr>
<td>Molecular characterization of blast cells</td>
<td>Immunophenotype/molecular phenotypes analogous to those defined in ALL</td>
<td>By analogy to ALL, specific molecular phenotypes have prognostic significance.</td>
<td>I</td>
</tr>
<tr>
<td>International Pediatric non-Hodgkin lymphoma staging system</td>
<td>Recently, a multidisciplinary expert panel proposed a revised INHLSS to address some of the shortcomings of the St. Jude staging classification.</td>
<td>Pending further study. As this classification gains more acceptance, AJCC will consider its use in the future for uniformity in management of children with NHL and will facilitate comparisons of study results.</td>
<td>II</td>
</tr>
</tbody>
</table>

Risk Assessment Models
The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use. Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.
80.2. Pediatric Hodgkin and Non-Hodgkin Lymphomas:
Pediatric Non-Hodgkin Lymphomas

Recommendations for Clinical Trial Stratification
The authors have not provided any recommendations for clinical trial stratification at this time.

Bibliography